Published in Circ Res on November 01, 1969
Control plasma renin activity and changes in sympathetic tone as determinants of minoxidil-induced increase in plasma renin activity. J Clin Invest (1975) 1.07
Variations in arterial blood pressure after kidney transplantation. Relation to renal function, plasma renin activity, and the dose of prednisone. Circulation (1973) 0.93
Comparative study of alprenolol and methyldopa in previously untreated essential hypertension. Br Heart J (1973) 0.86
Plasma renin activity in acute poststreptococcal glomerulonephritis and the haemolytic-uraemic syndrome. Arch Dis Child (1974) 0.84
Plasma renin activity in patients undergoing surgery of the abdominal aorta. Ann Surg (1974) 0.82
Comparative studies of guanfacine and methyldopa. Br J Clin Pharmacol (1980) 0.75
Myonecrosis after revascularization procedures. J Am Coll Cardiol (1998) 2.11
The potential of health sector non-governmental organizations: policy options. Health Policy Plan (1994) 1.98
Cable parameters, sodium, potassium, chloride, and water content, and potassium efflux in isolated external intercostal muscle of normal volunteers and patients with myotonia congenita. J Clin Invest (1971) 1.87
Causes and outcome of young infant admissions to a Kenyan district hospital. Arch Dis Child (2003) 1.81
Sodium, potassium, and chloride fluxes in intercostal muscle from normal goats and goats with hereditary myotonia. J Gen Physiol (1966) 1.72
A clinical and genetic study of the Say/Barber/Biesecker/Young-Simpson type of Ohdo syndrome. Clin Genet (2008) 1.71
The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysis. J Hum Hypertens (2008) 1.51
The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther (1978) 1.51
Medication use by ambulatory elderly. An in-home survey. J Am Geriatr Soc (1986) 1.44
THE EFFECTS OF AUTONOMIC NERVOUS SYSTEM INHIBITION ON THE CIRCULATORY RESPONSE TO MUSCULAR EXERCISE. J Clin Invest (1962) 1.41
Combination products as first-line pharmacotherapy. Arch Intern Med (1994) 1.41
Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet (1992) 1.41
Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? J Med Genet (1994) 1.33
The effects of injected norepinephrine and sympathetic nerve stimulation in hypothyroid and hyperthyroid dogs. J Pharmacol Exp Ther (1965) 1.29
In vivo measurements of macular and nerve fibre layer thickness in retinal arterial occlusion. Eye (Lond) (2006) 1.28
Postprandial alterations in hemodynamics and blood pressure in normal subjects. Am J Cardiol (1986) 1.25
Attitudes towards blood donation in Trinidad and Tobago. Transfus Med (2007) 1.20
Abnormal blood glucose concentrations on admission to a rural Kenyan district hospital: prevalence and outcome. Arch Dis Child (2003) 1.18
Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther (1972) 1.17
A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. Br J Cancer (1995) 1.17
Variability of myotonic signs in myotonic goats. Am J Vet Res (1968) 1.15
MLL2 mutation detection in 86 patients with Kabuki syndrome: a genotype-phenotype study. Clin Genet (2013) 1.13
Functional domains of the HIV-1 rev gene required for trans-regulation and subcellular localization. Virology (1990) 1.13
Self-rated health as a predictor of hospital admission and nursing home placement in elderly public housing tenants. Am J Public Health (1986) 1.11
Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther (1979) 1.10
Testing for the existence of a desirable dose combination. Biometrics (1993) 1.10
The Viking viewer for connectomics: scalable multi-user annotation and summarization of large volume data sets. J Microsc (2011) 1.07
Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord (2013) 1.05
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Genes Chromosomes Cancer (1997) 1.03
Interfamilial phenotypic heterogeneity in SMARD1. Neuromuscul Disord (2009) 1.03
4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther (1980) 1.00
Bartter's syndrome: urinary prostaglandin E-like material and kallikrein; indomethacin effects. Ann Intern Med (1977) 0.99
Orthostatic hypotension with brainstem tumors. Neurology (1984) 0.99
p53 inhibits mRNA 3' processing through its interaction with the CstF/BARD1 complex. Oncogene (2011) 0.98
A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants. Arch Dis Child (2004) 0.98
Factors contributing to medication noncompliance in elderly public housing tenants. Drug Intell Clin Pharm (1986) 0.98
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites. Clin Pharmacol Ther (1981) 0.98
Effects of yohimbine on squid axons. Biophys J (1978) 0.97
Hutchinson-Gilford progeria syndrome: clinical findings in three patients carrying the G608G mutation in LMNA and review of the literature. Br J Dermatol (2007) 0.97
Use of polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with human immunodeficiency virus infection. Neurology (1993) 0.97
Assessment of right ventricular systolic function using tricuspid annular-plane systolic excursion in Nigerians with systemic hypertension. Cardiovasc J Afr (2010) 0.96
Depression among adolescents, aged 13-19 years, attending secondary schools in Trinidad: prevalence and associated factors. West Indian Med J (2008) 0.93
Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol (1983) 0.92
Reversal of sympathetic nerve blockade: a comparison of dopa, dopamine, and norepinephrine with their alpha-methylated analogues. J Pharmacol Exp Ther (1965) 0.92
Current practices and medico-legal aspects of pre-operative consent. East Afr Med J (2004) 0.92
Does phospholipid flip-flop affect axon potassium channels? Biophys J (1975) 0.90
Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer. Genes Chromosomes Cancer (1998) 0.90
Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther (1984) 0.90
Diphenylhydantoin inhibition of sodium conductance in squid giant axon. Proc Natl Acad Sci U S A (1972) 0.90
Phosphopeptide quantitation using amine-reactive isobaric tagging reagents and tandem mass spectrometry: application to proteins isolated by gel electrophoresis. Rapid Commun Mass Spectrom (2006) 0.89
Sodium currents in human skeletal muscle fibers. Muscle Nerve (1982) 0.89
Probucol and the QT interval. Lancet (1982) 0.89
[A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)]. Nouv Presse Med (1980) 0.88
Effect of +Gz and +Gx acceleration on peripheral venous ADH levels in humans. J Appl Physiol (1967) 0.88
Male and female salivary testosterone concentrations before and after sexual activity. Physiol Behav (1992) 0.87
A precursor of the nitric oxide donor SIN-1 modulates the stress protein heme oxygenase-1 in rat liver. Biochem Biophys Res Commun (1996) 0.86
Determination of K(+)-channel relaxation times in squid axon membrane by Hodgkin-Huxley and by direct linear analysis. Biophys Chem (1991) 0.86
Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther (1979) 0.86
The pharmacology and clinical evaluation of aprindine a new antiarrhythmic agent. Acta Cardiol (1974) 0.86
Global guidelines for treatment of tuberculosis among persons living with HIV: unresolved issues. Int J Tuberc Lung Dis (2012) 0.86
For the first time in man. Clin Pharmacol Ther (1972) 0.85
Isopropylamine, a biologically active deamination product of propranolol in dogs: identification of deuterated and unlabeled isopropylamine by gas chromatography-mass spectrometry. J Pharmacol Exp Ther (1972) 0.85
p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers (1993) 0.85
Stimulation-induced release of propranolol and norepinephrine from adrenergic neurons. J Pharmacol Exp Ther (1979) 0.84
Temperature effects on cable parameters and K efflux in normal and myotonic goat muscle. Am J Physiol (1972) 0.84
Adrenergic blocking and cardiovascular effects of a new N-substituted tetrahydroisoquinoline (NC 7197). J Pharmacol Exp Ther (1971) 0.84
Sickle cell disease in permanent residents of mountain and low altitudes in Saudi Arabia. Trop Geogr Med (1990) 0.84
Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history. J Med Genet (2000) 0.84
The effects of positive and negative life changes on the self-reported health status of elderly adults. J Gerontol (1986) 0.84
Bone changes in sickle cell anaemia. East Afr Med J (1993) 0.84
Knowledge, attitudes and practices of anabolic steroid usage among gym users in Trinidad. West Indian Med J (2000) 0.83
A plasma humoral factor of extrarenal origin causing release of reninlike activity in hypotensive dogs. Circ Res (1971) 0.83
Adrenergic nerve stimulation-induced release of propranolol from the perfused hindlimb and spleen of the dog and associated changes in postjunctional response. J Pharmacol Exp Ther (1983) 0.83
Survival of patients with sickle cell anemia living at high altitude. South Med J (1990) 0.82
Demethylation of nortriptyline by the dog lung. J Pharmacol Exp Ther (1972) 0.82
Characteristics and outcome of cardiopulmonary resuscitation in hospitalised African children. Resuscitation (2008) 0.82
Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol (1985) 0.82
Stereoselective ring oxidation of propranolol in man. Br J Clin Pharmacol (1984) 0.82
Genetic predictors of cardiovascular morbidity in Bardet-Biedl syndrome. Clin Genet (2014) 0.81
Depolarization-induced release of propranolol and atenolol from rat cortical synaptosomes. Br J Pharmacol (1985) 0.81
Furosemide increases urine 6-keto-prostaglandin F1 alpha. Relation to natriuresis, vasodilation, and renin release. Hypertension (1982) 0.81
Comparative effects of currently available antihypertensive agents on spontaneously and renal hypertensive rats. Am J Med Sci (1970) 0.81
Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther (1994) 0.81
O-methylated catechol-like metabolites of propranolol in man. Drug Metab Dispos (1978) 0.80
Effects of centrally administered propranolol on plasma renin activity, plasma norepinephrine and arterial pressure. Eur J Pharmacol (1979) 0.80
Cerebroventricular propranolol elevates cerebrospinal fluid norepinephrine and lowers blood pressure. Science (1981) 0.80
Renin activity during supine exercise in normotensives and hypertensives. J Appl Physiol (1966) 0.80
A stereoselective central hypotensive action of atenolol. J Pharmacol Exp Ther (1989) 0.80
The effect of L-dopa on chronotropic responses to cardioaccelerator nerve stimulation in dogs. J Pharmacol Exp Ther (1971) 0.80
Identification of 5-meta-hydroxyphenyl-5-phenylhydantoin as a metabolite of diphenylhydantoin. Biochem Pharmacol (1970) 0.80
The clinical pharmacology of antihypertensive drugs. Prog Cardiovasc Dis (1969) 0.80
Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites. J Pharmacol Exp Ther (1987) 0.79
Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet. Clin Pharmacol Ther (1987) 0.79